OTLK•benzinga•
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $21
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 6, 2025 by benzinga